Results of HLA class II typing in 2022
| Trials | Specimen | Resolution | HLA-DR | No. of labs | HLA-DQ | No. of labs | DP | No. of labs |
|---|---|---|---|---|---|---|---|---|
| 1st | IHL-22-01 | Generic type | DRB1*09/DRB1*10 | 65 | DQB1*03/DQB1*05 | 47 | DPB1*05/Blank | 8 |
| Allelic type | DRB1*09:01/DRB1*10:01 | 30 | DQB1*03:03/DQB1*05:01 | 22 | DPB1*05:01/DPB1*99:99 | 8 | ||
| DRB1*09:01G/DRB1*10:01G | 2 | |||||||
| Serological equivalent | DR9/DR10 | 65 | DQ5/DQ9 | 47 | ||||
| IHL-22-02 | Generic type | DRB1*04/DRB1*14 | 65 | DQB1*03/DQB1*05 | 47 | DPB1*02/DPB1*05 | 8 | |
| Allelic type | DRB1*04:06/DRB1*14:01 | 3 | DQB1*03:02/DQB1*05:03 | 22 | DPB1*02:01/DPB1*05:01 | 8 | ||
| DRB1*04:06/DRB1*14:54 | 27 | |||||||
| DRB1*04:06G/DRB1*14:01G | 2 | |||||||
| Serological equivalent | DR4/Blank | 2 | DQ5/DQ8 | 47 | ||||
| DR4/DR14 | 63 | |||||||
| 2nd | IHL-19-03 | Generic type | DRB1*04/DRB1*08 | 65 | DQB1*04/DQB1*06 | 47 | DPB1*03/DPB1*05 | 10 |
| Allelic type | DRB1*04:05/DRB1*08:03 | 28 | DQB1*04:01/DQB1*06:01 | 21 | DPB1*03:01/DPB1*05:01 | 10 | ||
| DRB1*04:05G/DRB1*08:03G | 1 | |||||||
| Serological equivalent | DR4/DR8 | 65 | DQ4/DQ6 | 47 | ||||
| IHL-19-04 | Generic type | DRB1*13/Blank | 65 | DQB1*06/Blank | 47 | DPB1*02/DPB1*04 | 10 | |
| Allelic type | DRB1*13:02/DRB1*13:02 | 3 | DQB1*06:04/DQB1*99:99 | 21 | DPB1*02:01/DPB1*: | 1 | ||
| DRB1*13:02/DRB1*99:99 | 25 | DPB1*02:01/DPB1*04:01 | 9 | |||||
| DRB1*13:02G/DRB1*99:99 | 1 | |||||||
| Serological equivalent | DR13/Blank | 65 | DQ6/Blank | 47 |
Bold letter indicates the results which are not compliant with the intended responses.
Abbreviation: HLA, human leukocyte antigen.